Indonesia Diabetes Drug Market Overview, 2030

The diabetes drug market has grown into one of the most critical segments of the pharmaceutical industry, driven by the alarming rise in diabetes prevalence, technological advances, and evolving treatment protocols. Diabetes, particularly Type 2, is increasingly being diagnosed across both developed and developing nations due to sedentary lifestyles, unhealthy diets, aging populations, and genetic predisposition. The World Health Organization (WHO) estimates that over 422 million people worldwide have diabetes, with a large proportion residing in low- and middle-income countries. Consequently, the demand for diabetes drugs continues to rise significantly. The diabetes drug market is its consistent double-digit growth, even when other therapeutic areas experience stagnation. This is largely because diabetes is a chronic condition with no permanent cure, requiring lifelong medication and monitoring. Another compelling feature of this market is the increasing diagnosis rate among younger demographics. Traditionally seen as a middle-aged disease, Type 2 diabetes is now being observed in younger adults and even adolescents due to rising obesity and poor lifestyle habits. This shift is reshaping how pharmaceutical companies approach drug development, marketing, and accessibility. Additionally, drug companies are heavily investing in GLP-1 receptor agonists and SGLT2 inhibitors due to their added cardiovascular and renal benefits, expanding their therapeutic relevance beyond glucose control. Regulations also play a significant role in shaping the diabetes drug market. Agencies such as the U.S. FDA, the European Medicines Agency (EMA), and respective national regulators impose stringent approval processes for safety, efficacy, and manufacturing standards. In recent years, regulators have begun to emphasize real-world evidence (RWE) and post-market surveillance to ensure long-term drug safety and effectiveness. Many governments have also initiated national diabetes control programs and subsidies for essential medicines, encouraging greater treatment coverage.

The demand for affordable and accessible medications is rapidly expanding, creating lucrative opportunities for both branded and generic drug manufacturers. The growing awareness and early diagnosis of diabetes, aided by health education campaigns, widespread screening programs, and digital health platforms that encourage preventive care and timely intervention. This has led to earlier initiation of pharmacological treatment, further pushing drug consumption volumes. The rise in comorbidities such as cardiovascular disease, kidney disorders, and obesity among diabetic patients has also intensified the demand for multi-functional drugs that offer more than just glucose control. Economic factors also significantly contribute to market expansion. Governments across the globe are increasingly prioritizing diabetes care by including essential diabetes drugs in national reimbursement lists and offering subsidies, especially for insulin and metformin. Meanwhile, private insurance providers are expanding coverage to accommodate more advanced and expensive therapies, encouraging the uptake of newer drugs. Another noteworthy trend is the rise of online and digital pharmacy platforms, which has transformed distribution channels, especially in urban areas, allowing better access and affordability. Digital health integration is revolutionizing how diabetes drugs are prescribed, monitored, and adjusted. AI-powered tools, wearable glucose monitors, mobile apps, and telemedicine platforms are enabling real-time data sharing between patients and providers, leading to more customized and timely treatment adjustments. Pharmaceutical companies are increasingly bundling medications with digital monitoring tools to enhance outcomes, which are creating a new model of care that merges medication with technology. Regulatory support for such innovations, including fast-track approvals and incentive programs for novel therapies, is helping push the boundaries of traditional diabetes care.

Insulin continues to dominate as a fundamental treatment, especially for individuals with Type 1 diabetes and those with advanced Type 2 diabetes where oral medications no longer suffice. Demand for insulin remains strong due to its ability to provide direct glucose control, and newer formulations, such as rapid-acting and ultra-long-acting types, are improving patient convenience and adherence. GLP-1 receptor agonists have gained widespread attention for their dual role in lowering blood sugar and aiding in weight management, making them highly appealing for patients with coexisting obesity. These drugs also provide cardiovascular benefits, which add to their growing demand in comprehensive diabetes care. DPP-4 inhibitors are frequently chosen for their gentle mechanism of action, minimal risk of hypoglycemia, and suitability for a wide patient demographic, particularly those in the early stages of diabetes. Their oral administration and low side effect profile enhance patient compliance, contributing to their steady demand. SGLT2 inhibitors have emerged as one of the most rapidly growing classes due to their multifaceted benefits not only do they lower glucose levels by promoting glucose excretion through the urine, but they also offer protective effects for the heart and kidneys. This broader therapeutic utility makes them a preferred choice in modern diabetes management. The others category, which includes metformin, sulfonylureas, and combination therapies, continues to play a vital role. Metformin, being the first-line therapy, is valued for its safety, cost-effectiveness, and efficacy, while sulfonylureas are still used for their potent glucose-lowering effects despite some risks. Combination therapies, which integrate multiple classes in a single formulation, are increasingly adopted to enhance efficacy, reduce pill burden, and improve patient outcomes.

Type 1 diabetes, which is typically diagnosed in younger individuals, is an autoimmune condition that results in the body’s inability to produce insulin. As such, the market demand for insulin-based therapies is particularly high among this segment. These drugs are predominantly administered through subcutaneous routes, which allow for regular insulin intake to maintain blood glucose levels. On the other hand, Type 2 diabetes, which is more prevalent and usually develops in adulthood, is associated with insulin resistance or insufficient insulin production. The treatment for Type 2 diabetes often starts with oral medications like metformin, SGLT2 inhibitors, and DPP-4 inhibitors, which are in high demand due to ease of administration and patient compliance. However, in cases where oral medications are not sufficient, injectable drugs, including GLP-1 receptor agonists and insulin, are introduced, primarily via subcutaneous routes. Among the routes of administration, oral medications dominate the Type 2 segment because they are non-invasive and easier for long-term management, leading to better adherence. However, the subcutaneous route holds significant importance across both diabetes types due to the necessity of insulin and injectable therapies. GLP-1 receptor agonists, for instance, which are highly effective in controlling blood glucose and aiding in weight loss, are commonly administered subcutaneously and are seeing increasing demand due to dual benefits. The intravenous route is less commonly used but remains crucial in acute care settings, such as hospitals, where rapid glucose management is required, particularly during episodes of diabetic ketoacidosis or surgeries. This route ensures quick absorption and controlled dosing, though it is typically reserved for short-term or emergency applications.

Hospital pharmacies are essential in acute care management and are a primary source of insulin and injectable therapies, especially for newly diagnosed patients or those undergoing inpatient treatment. These settings often handle more complex cases that require immediate medical supervision and are well-stocked with a broad range of diabetes medications, including intravenous and subcutaneous options. The demand for hospital pharmacies remains strong due to their association with medical facilities and the need for precision in administering treatments. Retail pharmacies, on the other hand, dominate the outpatient segment and are highly preferred by patients managing diabetes on a long-term basis. These pharmacies are easily accessible and offer a wide selection of oral antidiabetic drugs, such as metformin, SGLT2 inhibitors, and DPP-4 inhibitors, which are popular among Type 2 diabetes patients. Retail pharmacies also provide subcutaneous injections, including insulin pens and GLP-1 receptor agonists, with growing demand as self-administration becomes more common. The role of retail pharmacies extends beyond drug dispensing they also support patient education and medication adherence programs, which are crucial for chronic disease management. Their presence in both urban and rural areas enhances reach and convenience, making them a vital distribution channel for maintaining regular treatment regimens. Online pharmacies are gaining rapid traction due to their convenience, discrete service, and the growing digitization of healthcare. The demand for this channel has surged, particularly among tech-savvy and elderly patients who prefer home delivery of their medications. Online platforms provide easy access to refills of oral and injectable diabetes drugs, and they often offer competitive pricing, subscription-based delivery models, and digital reminders to boost adherence.



Considered in this report
• Historic Year: 2019
• Base year: 2024
• Estimated year: 2025
• Forecast year: 2030

Aspects covered in this report
• Diabetic Drug Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Drug Class
• Insulin
• GLP-1 Receptor Agonists
• DPP-4 Inhibitors
• SGLT2 Inhibitors
• Others (metformin, sulfonylureas, and combination therapies)

By Diabetes
• Type-1
• Type-2

By Route of Administration
• Oral
• Subcutaneous
• Intravenous

By Distribution Channel
• Hospital Pharmacies
• Retail pharmacies
• Online Pharmacies

The approach of the report:
This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and listing out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, annual report of companies, analyzing the government generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducted trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers in regional aspects, tier aspects, age group, and gender. Once we have primary data with us we have started verifying the details obtained from secondary sources.

Intended audience
This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to this industry, government bodies and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.